Furthermore, with the introduction of various combinations of medications, such as VEGF inhibitors, programmed death-ligand 1 inhibitors, and PARP inhibitors in ovarian cancer treatment, systematic and diverse clinical trials are necessary to establish optimal treatment algorithms for patients with ovarian cancer. Here, PARP1 is linked to ovarian carcinoma.